Trial Profile
BioTRAC (BIOLOGIC TREATMENT REGISTRY ACROSS CANADA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2022
Price :
$35
*
At a glance
- Drugs Golimumab (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms BioTRAC
- Sponsors Janssen Inc; Merck & Co
- 14 Nov 2022 Results describing the long-term incidence of infection of RA pts treated with GLM in routine care, assessing the impact of infections on GLM retention, and exploring risk factors associated with infection presented at the ACR Convergence 2022
- 14 Nov 2022 Results of a post-hoc analysis assessing the risk of major adverse cardiovascular events (MACE), malignancy, and mortality in a large observational cohort of patients with RA, PsA, or axSpA treated with subcutaneous Golimumab, presented at the ACR Convergence 2022
- 04 Jun 2022 Results (n=530) of a post-hoc analysis assessing long-term incidence of infection, impact of infections on Golimumab retention and exploring factors associated with risk of infection in a cohort of Rheumatoid Arthritis patients in Canadapresented at the 23rd Annual Congress of the European League Against Rheumatism